What the FDA labels say about taking them together
Esomeprazole and octreotide
Octreotide's FDA label (Mycapssa) of July 24, 2025 names esomeprazole in its drug interactions section; the esomeprazole labels PlainMeds reads (3) do not name octreotide. The octreotide label: “Concomitant administration of MYCAPSSA with esomeprazole resulted in a decrease in the bioavailability for MYCAPSSA [ See ]. Drugs that alter the pH of the upper GI tract may alter the absorption of MYCAPSSA and lead to …”
Check it at the source: the esomeprazole FDA label on DailyMed (effective March 19, 2024, Haleon US Holdings LLC); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the esomeprazole label say about octreotide?
Esomeprazole's label (effective March 19, 2024) and its 2 other brand-application labels do not name octreotide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Nexium 24HR), NDA204655 (Astrazeneca Lp), as published by Haleon US Holdings LLC, effective March 19, 2024 (SPL set 4513934d-0cf0-40fc-a348-b4e75a33b094), via openFDA; the full label on DailyMed
What does the octreotide label say about esomeprazole?
Mycapssa label (Chiesi USA, Inc., July 24, 2025), drug interactionsProton Pump Inhibitors, H2-receptor Antagonists, or Antacids Clinical Impact: Concomitant administration of MYCAPSSA with esomeprazole resulted in a decrease in the bioavailability for MYCAPSSA [ See ]. Drugs that alter the pH of the upper GI tract (…) may alter the absorption of MYCAPSSA and lead to a reduction in bioavailability. Intervention: Co-administration of MYCAPSSA with PPIs, H2-blockers, or antacids may require increased doses of MYCAPSSA.
Source: FDA drug label (Mycapssa, NDA208232), Chiesi USA, Inc., effective July 24, 2025 (SPL set 58d80bc6-bdfb-4908-93e7-aace447c8d1a), via openFDA
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Esomeprazole | Octreotide | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Diarrhea |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.145 per capsule 20 mg capsule | $2.53 per mL 100 mcg/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once